ASCO 2019: Low-dose chemotherapy regimen effective in older and frail patients with gastroesophageal cancer

16 May 2019
ASCO 2019: Low-dose chemotherapy regimen effective in older and frail patients with gastroesophageal cancer

“‘Less is more’ is becoming a common refrain in some areas of cancer treatment, and one that is paying off for patients’ quality of life. This trial seeks to balance quality of life and increased survival for older and frail people receiving palliative treatment for gastroesophageal cancer, providing data that we sorely need for this patient population. These data are important because they provide a potential new option for patients to slow the progression of the disease,” said ASCO President Monica M. Bertagnolli, MD, FACS, FASCO.

The phase III GO2 randomised trial of 514 older and frail people in the United Kingdom with advanced gastroesophageal cancer found that the lowest tested dose of oxaliplatin (Eloxatin) and capecitabine (Xeloda) was comparable to the highest dose in terms of delaying disease progression and minimising side effects.

The study will be presented at the upcoming 2019 ASCO Annual Meeting in Chicago.

"Previous trials of palliative chemotherapy for gastric and esophageal cancer have not included frail or older patients, therefore the benefit of chemotherapy in these groups was unknown,” said lead study author Peter S. Hall, PhD, a Medical Oncologist at the University of Edinburgh, United Kingdom. “We hope our finding helps patients make a more informed choice, between low-dose chemotherapy and no chemotherapy at all, with the knowledge that that low-dose chemotherapy can prove beneficial and still allow them to maintain some quality of life while slowing the progression of the disease.”

Each year, more than 17,000 people in the United States are diagnosed with esophageal cancer, and the majority are older or frail and unable to tolerate the combination of three types of chemotherapy.

This cancer is usually diagnosed at a late stage and is the sixth most common cause of cancer deaths worldwide.

It is more common in men and older people, with a median age at diagnosis of 68.

The 5-year relative survival rate for advanced gastroesophageal cancer in the United States is 5%.2

About the Study

In a phase II trial in a similar population of older and frail patients with advanced gastroesophageal cancer, the combination of oxaliplatin, a therapy that inhibits DNA replication, and capecitabine, a therapy that inhibits tumour cell division, was found to be more effective at controlling disease than capecitabine alone.

It was also more effective than a combination that included oxaliplatin, capecitabine, and epirubicin (Ellence), which was too toxic and could not be tolerated.

Epirubicin inhibits DNA and RNA synthesis, resulting in cancer cell death.

This trial was designed to find the optimum dose of capecitabine and oxaliplatin for use in older or frail patients.

To determine optimal clinical benefit, tolerability, quality of life, and patient satisfaction, for the two-medicine therapy, researchers incorporated these factors and others into an assessment tool called Overall Treatment Utility, or OTU.

Between 2014 and 2017, investigators randomly assigned people, age 51 to 96, to three dosage levels.

Level A was 130 milligrams per meter squared of body surface area (mg/m2) of oxaliplatin given once every 21 days and a 625 mg/m2 dose of capecitabine twice a day given continuously.

Level B was 80% of Level A dosage and Level C was 60% of Level A dosage.

People with decreased kidney function received 75% of the suggested doses of capecitabine.

After 9 weeks, patients were assessed for OTU. Continuation of the medicines was based on the judgement of the physicians.

Key Findings

People who received Level C dosages had fewer toxic reactions to the medicines and better OTU outcomes than Levels A or B. 

Level C produced the best OTU even in younger, less frail people and no group benefited more from higher dosage levels.

Several secondary measures were also assessed.

Overall survival was comparable across doses: patients lived a median of 7.5 months at Level A dosages, 6.7 months for Level B, and 7.6 months for Level C.

Researchers also found the same times for progression-free survival (length of time without signs of the cancer progressing) across all three levels: people receiving Level A doses lived a median of 4.9 months, Level B a median of 4.1 months, and Level C a median of 4.3 months, all without signs of the disease worsening.

Side effects of grade 3 or more, which can often be serious, were seen in 56% of people getting Level A and B doses but were seen in only 37% of people getting Level C doses.

People getting Level C doses also had a higher percentage of good OTU scores (43%) compared to Levels A and B (35% and 36% respectively).

Source: American Society of Clinical Oncology